Read the history in context
Records, not a safety rating.
Recall counts do not account for sales volume, exposure or differences in reporting. Agency records can overlap. A low count does not establish that a brand or product is safe.
View source coverage →Severity Breakdown
Class I — Serious
0Class II — Moderate
0Class III — Low Risk
0Unclassified
1Categories
MEDICATION
Recall Timeline
FDAAug 11, 2026
Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles
FOR IMMEDIATE RELEASE – August 10, 2026 – LAKE ZURICH, Ill.— Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to cont
Track Fresenius Kabi Issues Nationwide recalls automatically
Get an alert when a matching Fresenius Kabi Issues Nationwide recall turns up.
Start Free Trial